Proposal for MitoQ

Overview of Therapeutic Candidate:
MitoQ is a synthetic, mitochondria‐targeted antioxidant that was developed by conjugating a ubiquinone (coenzyme Q10) derivative to a lipophilic triphenylphosphonium (TPP⁺) cation. This chemical modification enables the compound to selectively accumulate within mitochondria, driven by the large negative membrane potential of the inner mitochondrial membrane. As a member of the mitochondria‐targeted antioxidant class, MitoQ was originally designed to address oxidative stress by delivering its redox‐active moiety directly to the site of reactive oxygen species (ROS) generation within mitochondria. This class of compounds has been previously employed in several domains, including cardiovascular and metabolic disorders, neurodegenerative diseases, and conditions marked by mitochondrial dysfunction. Their design overcomes the limitations of untargeted antioxidants by ensuring that the antioxidant is present at sufficiently high concentrations within the mitochondria to be effective. The ability of MitoQ to permeate lipid bilayers due to its TPP⁺ moiety and to concentrate several hundred‐fold inside mitochondria has been well documented in preclinical studies, making it a promising candidate for addressing diseases with a mitochondrial component (Smith et al., 2008).

Therapeutic History:
MitoQ’s history spans both preclinical and clinical investigations. Preclinical studies have demonstrated that MitoQ can effectively scavenge mitochondrial ROS and protect mitochondrial components from oxidative damage. In several neuronal and fibroblast models, treatment with MitoQ resulted in improved mitochondrial respiration, increased ATP production, and enhanced oxygen consumption rate (OCR), suggesting a potent bioenergetic benefit (Yin et al., 2016). Beyond its preclinical promise, MitoQ has advanced into clinical evaluation for various conditions such as Parkinson’s disease, hepatitis C, sickle cell anemia, multiple sclerosis, and peripheral arterial disease. These studies established its oral bioavailability and safety profile in humans (ClinicalTrials.gov, 2024; ClinicalTrials.gov, 2020; ClinicalTrials.gov, 2023). Although direct clinical trials targeting Friedreich’s Ataxia (FRDA) have not yet been reported, several clinical investigations in related disorders involving mitochondrial dysfunction underline its translational readiness (ClinicalTrials.gov, n.d.).

Mechanism of Action:
MitoQ exerts its antioxidant effects via a well‐characterized mechanism that involves several key biochemical steps. The TPP⁺ moiety attached to the ubiquinone confers rapid and selective mitochondrial uptake; once inside the mitochondrial matrix, MitoQ is reduced by components of the electron transport chain, primarily complex II, to form the active ubiquinol species. This reduced form acts as a potent antioxidant that scavenges ROS, particularly at the inner mitochondrial membrane where oxidative damage is most pronounced. By neutralizing ROS, MitoQ helps to prevent lipid peroxidation of mitochondrial membranes and protects critical mitochondrial proteins, including those containing iron‐sulfur (Fe‐S) clusters. In Friedreich’s Ataxia, the deficiency in frataxin leads to impaired synthesis and stability of Fe‐S cluster proteins, resulting in reduced electron transport chain activity and diminished ATP production. MitoQ’s mechanism is expected to mitigate these defects by lowering the burden of oxidative damage on Fe‐S proteins such as aconitase and complex I, thereby preserving their function. Additionally, by reducing the oxidative stress within mitochondria, MitoQ may enhance overall mitochondrial coupling efficiency and support improved oxygen consumption rates (OCR) (Rodríguez et al., 2020; Smith et al., 2008).

Expected Effect:
The central hypothesis for repurposing MitoQ in Friedreich’s Ataxia is that its targeted antioxidant action will protect mitochondrial integrity by scavenging ROS at the site of their production—the inner mitochondrial membrane. In FRDA, oxidative stress is both a cause and consequence of mitochondrial dysfunction and impaired Fe‐S cluster assembly. With frataxin deficiency, ROS levels increase and contribute to the degradation of critical Fe‐S cluster–containing enzymes, such as mitochondrial aconitase and components of complex I. It is expected that MitoQ, by virtue of its selective accumulation in mitochondria, will reduce the levels of ROS sufficiently to prevent secondary damage to these proteins. Moreover, by alleviating oxidative stress, MitoQ should improve mitochondrial coupling efficiency, thereby promoting enhanced ATP production and higher OCR in affected neuronal and fibroblast cells. Since Fe‐S clusters are pivotal for the function of several enzymes in the respiratory chain, maintaining their integrity could reverse or slow the progression of mitochondrial dysfunction observed in FRDA. Several biochemical studies have indicated that mitochondria‐targeted antioxidants can improve enzyme function and bioenergetics in disease models characterized by mitochondrial oxidative stress (Marmolino, 2011; Rodríguez et al., 2020). Thus, the expected effect of MitoQ in FRDA is a protective restoration of mitochondrial function that translates into improved cellular energy metabolism, which could ultimately impact the neurodegenerative and cardiomyopathic phenotypes of the disease (Rodríguez et al., 2020; Cooper & Schapira, 2003).

Overall Evaluation:
MitoQ represents a strong candidate for repurposing in the treatment of Friedreich’s Ataxia due to several compelling reasons. One significant strength of MitoQ is its clearly defined mechanism of action: the compound selectively accumulates within mitochondria via its TPP⁺ conjugate, where it is converted to its active antioxidant form, thus directly neutralizing mitochondrial ROS and reducing oxidative stress (Smith et al., 2008; Szeto, 2006). This targeted delivery is particularly advantageous in FRDA, where mitochondrial oxidative damage plays a central role in the progression of neurodegeneration and cardiomyopathy. Additionally, preclinical data showing improvements in ATP production and OCR in neuronal and fibroblast models provide strong biochemical support for the use of MitoQ in conditions marked by impaired mitochondrial bioenergetics (Yin et al., 2016).

From a therapeutic history standpoint, MitoQ has been tested in a number of clinical settings involving diseases with oxidative stress and mitochondrial dysfunction, and its safety profile in humans is well‐established through multiple clinical trials (ClinicalTrials.gov, 2024; ClinicalTrials.gov, 2020; ClinicalTrials.gov, 2023). This existing clinical data significantly de‐risks its repurposing for FRDA by providing evidence of oral bioavailability and tolerability in humans. However, a weakness is that, to date, direct clinical evidence for its efficacy in Friedreich’s Ataxia is lacking, and most of the supportive data come from other disease models or preclinical studies (Rodríguez et al., 2020; Cooper & Schapira, 2003).

The detailed mechanism of action, as described, aligns well with the known pathophysiological features of FRDA. By protecting Fe‐S cluster proteins from ROS‐mediated damage, MitoQ has the potential to restore normal mitochondrial function, thereby ameliorating energy deficits and reducing the cascade of cellular dysfunction that leads to neurodegeneration. The expected biochemical improvements, including increased coupling efficiency, higher ATP production, and elevated OCR, are highly relevant to the bioenergetic defects observed in FRDA (Rodríguez et al., 2020; Marmolino, 2011; Voncken et al., 2004).

In summary, the strengths of MitoQ include its targeted mitochondrial delivery, robust antioxidant mechanism, demonstrated improvements in mitochondrial bioenergetics in relevant preclinical models, and proven oral bioavailability and safety from existing clinical trials. These factors collectively endorse its potential as a promising therapeutic candidate for Friedreich’s Ataxia. On the other hand, the lack of direct clinical data in FRDA patients and the possibility that its mechanism may only address secondary oxidative damage rather than the primary defect in Fe‐S cluster biogenesis are notable weaknesses. Overall, MitoQ appears to be a rational candidate for further preclinical validation in FRDA models, with the goal of subsequently designing targeted clinical trials to rigorously assess its efficacy in correcting the mitochondrial dysfunction central to FRDA pathology (Rodríguez et al., 2020; Marmolino, 2011; Voncken et al., 2004).

References:
ClinicalTrials.gov. (n.d.). Clinical trial search: MitoQ Friedreich’s ataxia OR mitochondria‐targeted antioxidants Friedreich’s ataxia. Retrieved from https://clinicaltrials.gov

Cooper, J. M., & Schapira, A. H. V. (2003). Friedreich’s ataxia: Disease mechanisms, antioxidant and coenzyme Q10 therapy. BioFactors, 18, 163–171. https://doi.org/10.1002/biof.5520180219

Marmolino, D. (2011). Friedreich’s ataxia: Past, present and future. Brain Research Reviews, 67, 311–330. https://doi.org/10.1016/j.brainresrev.2011.04.001

Rodríguez, L. R., Lapeña, T., Calap-Quintana, P., Moltó, M. D., Gonzalez-Cabo, P., & Navarro Langa, J. A. (2020). Antioxidant therapies and oxidative stress in Friedreich’s ataxia: The right path or just a diversion? Antioxidants, 9, Article 664. https://doi.org/10.3390/antiox9080664

Smith, R. A. J., Adlam, V. J., Blaikie, F. H., Manas, A.-R. B., Porteous, C. M., James, A. M., Ross, M. F., Logan, A., Cochemé, H. M., Trnka, J., Prime, T. A., Abakumova, I., Jones, B. A., Filipovska, A., & Murphy, M. P. (2008). Mitochondria‐targeted antioxidants in the treatment of disease. Annals of the New York Academy of Sciences, 1147, 105–111. https://doi.org/10.1196/annals.1427.003

Szeto, H. H. (2006). Mitochondria‐targeted peptide antioxidants: Novel neuroprotective agents. The AAPS Journal, 8, E521–E531. https://doi.org/10.1208/aapsj080362

University of Edinburgh. (2024). Mini-MARVEL: Mitochondrial antioxidant therapy in ulcerative colitis (NCT05539625) [Clinical trial registration]. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05539625

University of Nebraska. (2023). MitoQ treatment of claudication: Myofiber and micro-vessel pathology (NCT06409949) [Clinical trial registration]. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06409949

VA Office of Research and Development. (2020). MitoQ for fatigue in multiple sclerosis (MS) (NCT04267926) [Clinical trial registration]. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04267926

Voncken, M., Ioannou, P., & Delatycki, M. B. (2004). Friedreich ataxia: Update on pathogenesis and possible therapies. Neurogenetics, 5, 1–8. https://doi.org/10.1007/s10048-003-0170-z

Yin, X., Manczak, M., & Reddy, P. H. (2016). Mitochondria‐targeted molecules MitoQ and SS31 reduce mutant huntingtin‐induced mitochondrial toxicity and synaptic damage in Huntington’s disease. Human Molecular Genetics, 25, 1739–1753. https://doi.org/10.1093/hmg/ddw045
